5 Years Follow-up of the Study: Pharmacogenetics in Depressed Patients with Focus on Difficult-to-Treat Depression, Suicide Attempt, and CYP2D6

What this Trial Is About

Researchers are investigating the long-term outlook and factors predicting treatment results for people with difficult-to-treat depression under secondary psychiatric care. This study follows a group of 415 patients originally studied between 2012 and 2021, who were carefully assessed for their diagnosis and previous treatments. All participants were genotyped for enzymes CYP2D6 and CYP2C19, and blood samples were stored for further analysis related to prognosis. The current study involves a five-year follow-up of these patients through review of medical records and national register data. No new treatments or interventions are provided during this period. Data collected will include information on suicide attempts, hospital visits, treatments received, personality assessments, and clinical improvements. The study aims to examine symptom patterns, the clinical course of depression, suicidality, and the impact of earlier pharmacological counseling offered to some participants. Participants' involvement consists of allowing access to their medical and registry data for a period of five years after the original study. Researchers will track clinical outcomes such as suicide attempts, depression progression, personality disorder diagnoses, bipolar disorder characteristics, and biomarker effects. The study uses approved opt-out consent, where participants can decline but are otherwise included. The total follow-up period is five years from each participant's baseline enrollment in the original study.

Long-term Follow-up of Depressive Disorders in Psychiatric Care